Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass
Trial end date:
SummaryThe aim of this study is investigating the effect of a novel glucagon analogue administration in gastric bypass operated individuals, who are reactive hypoglycemic.
Accepts Healthy Volunteers?Accepts Healthy Volunteers
University Hospital, Gentofte, Copenhagen
- Documented postprandial hypoglycaemia (<3.9 mmol/l) by 6-day CGM or during a MMT
- Documented plasma glucose concentration excursions >5.0 mmol/l by 6-day CGM or a MMT
- Haemoglobin levels for women >7.3 mmol/l and for men >8.3 mmol/l
- Ferritin >10 μg/l
- Cobalamin >150 pmol/l
- Fasting plasma glucose concentration within the range of 4.0-6.0 mmol/l CKN-DASI-RYGB
protocol version 1.0 6
- Normal electrocardiogram (ECG)
- Negative urine human chorionic gonadotropin (hCG) (for fertile women)
- Treatment with medication(s) affecting insulin secretion or any antidiabetic drugs
- Treatment with antipsychotics
- Current participation in another clinical trial with administration of investigational
- Previous exposure to dasiglucagon (otherwise known as ZP4207)
- History of liver disease that is expected to interfere with the anti-hypoglycaemic
action of glucagon (e.g. liver failure or cirrhosis).
- Any factors that, in the opinion of the site principal investigator or clinical
protocol chair, would interfere with the safe completion of the study, including
medical conditions that may require hospitalization during the trial or allergy to the
ingredients in the study drug.